TAK-981
Solid tumors
Phase 1/2Active
Key Facts
About Takeda Pharmaceutical
Founded in 1781, Takeda is a leading global biopharmaceutical company headquartered in Tokyo, Japan, with operations in over 80 countries. The company transformed through strategic acquisitions including Shire in 2019, building a diversified portfolio in oncology, rare diseases, neuroscience, and gastroenterology. Takeda focuses on developing breakthrough therapies while maintaining a strong commercial presence with blockbuster drugs generating billions in annual revenue.
View full company profileTherapeutic Areas
Other Solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Phase 2 |
| ONO-4538 combinations | Ono Pharmaceutical | Phase 2 |